SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Biogen Inc. (BIIB) trades at a trailing P/E of 20.2, forward P/E of 11.6. Trailing earnings yield is 4.96%, forward earnings yield 8.66%. PEG 0.15 (Peter Lynch undervalued ≤1.0). Graham Number is $157.12.
Criteria proven by this page:
- VALUE (47/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 11.6 (down from trailing 20.2) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.15 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.96% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 8.66% as earnings recover.
- Analyst consensus target $207.60 (+16% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 60/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
47/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BIIB
Valuation Multiples
P/E (TTM)20.2
Forward P/E11.6
PEG Ratio0.15
Forward PEG0.15
P/B Ratio1.43
P/S Ratio2.66
EV/EBITDA9.7
Per Share Data
EPS (TTM)$8.82
Forward EPS (Est.)$15.50
Book Value / Share$124.45
Revenue / Share$66.88
FCF / Share$14.58
Yields & Fair Value
Earnings Yield4.96%
Forward Earnings Yield8.66%
Dividend Yield0.00%
Graham Number$157.12
SharesGrow IV$279.46 (+56.2%)
Analyst Target$207.60 (+16%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
16.7 |
1.63 |
5.10 |
5.41 |
- |
| 2017 |
26.7 |
-0.90 |
5.37 |
5.52 |
- |
| 2018 |
13.9 |
0.17 |
4.73 |
4.58 |
- |
| 2019 |
9.4 |
0.21 |
4.16 |
3.86 |
- |
| 2020 |
9.8 |
-0.47 |
3.68 |
2.93 |
- |
| 2021 |
23.0 |
-0.40 |
3.28 |
3.26 |
- |
| 2022 |
13.2 |
0.13 |
3.00 |
3.96 |
- |
| 2023 |
32.2 |
-0.52 |
2.53 |
3.81 |
- |
| 2024 |
13.7 |
0.34 |
1.33 |
2.30 |
- |
| 2025 |
20.0 |
-0.95 |
1.41 |
2.63 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$16.93 |
$11.45B |
$3.7B |
32.3% |
| 2017 |
$11.92 |
$12.27B |
$2.54B |
20.7% |
| 2018 |
$21.58 |
$13.45B |
$4.43B |
32.9% |
| 2019 |
$31.42 |
$14.38B |
$5.89B |
41% |
| 2020 |
$24.80 |
$13.44B |
$4B |
29.8% |
| 2021 |
$10.40 |
$10.98B |
$1.56B |
14.2% |
| 2022 |
$20.87 |
$10.17B |
$3.05B |
29.9% |
| 2023 |
$7.97 |
$9.84B |
$1.16B |
11.8% |
| 2024 |
$11.19 |
$9.68B |
$1.63B |
16.9% |
| 2025 |
$8.83 |
$9.81B |
$1.29B |
13.2% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$15.76 |
$13.55 – $17.28 |
$9.43B |
$9.27B – $10.05B |
20 |
| 2027 |
$16.18 |
$13.57 – $18.31 |
$9.36B |
$8.74B – $10.13B |
18 |
| 2028 |
$17.34 |
$16.37 – $19.08 |
$9.47B |
$9.46B – $9.49B |
6 |
| 2029 |
$17.96 |
$17.00 – $19.48 |
$9.53B |
$9.13B – $10.14B |
4 |
| 2030 |
$18.14 |
$17.17 – $19.67 |
$9.6B |
$9.21B – $10.23B |
2 |
